CompletedEarly Phase 1

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women

Thailand129 participantsStarted 2018-05-09

Plain-language summary

This study evaluated the seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women. All seronegative participants received Tdap, while seropositive participants were equally randomized into 2 groups. Half of seropositive participants received Tdap and the other half received tetanus-diphtheria (Td) as standard protocol.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. History of serious allergic reaction to any components of Tdap vaccine
✕. History of seizure or coma after receiving Tdap vaccine in childhood
✕. Having an underlying disease involving central nervous system (e.g., epilepsy, Guillain-Barré syndrome)

What they're measuring

The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai Women

Timeframe: Four months

Trial details

NCT IDNCT03498300

SponsorMahidol University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-04-13

Results submitted2019-11-24

View on ClinicalTrials.gov More Pertussis trials